EP1370252A4 - Mimetiques de la thrombopoietine - Google Patents

Mimetiques de la thrombopoietine

Info

Publication number
EP1370252A4
EP1370252A4 EP02728383A EP02728383A EP1370252A4 EP 1370252 A4 EP1370252 A4 EP 1370252A4 EP 02728383 A EP02728383 A EP 02728383A EP 02728383 A EP02728383 A EP 02728383A EP 1370252 A4 EP1370252 A4 EP 1370252A4
Authority
EP
European Patent Office
Prior art keywords
thrombopoietin mimetics
thrombopoietin
mimetics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02728383A
Other languages
German (de)
English (en)
Other versions
EP1370252A1 (fr
Inventor
Kevin J Duffy
Juan I Luengo
Antony N Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1370252A1 publication Critical patent/EP1370252A1/fr
Publication of EP1370252A4 publication Critical patent/EP1370252A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/04—Nitro compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP02728383A 2001-03-01 2002-03-01 Mimetiques de la thrombopoietine Withdrawn EP1370252A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26995801P 2001-03-01 2001-03-01
US269958P 2001-03-01
PCT/US2002/006259 WO2002085343A1 (fr) 2001-03-01 2002-03-01 Mimetiques de la thrombopoietine

Publications (2)

Publication Number Publication Date
EP1370252A1 EP1370252A1 (fr) 2003-12-17
EP1370252A4 true EP1370252A4 (fr) 2006-04-05

Family

ID=23029313

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02728383A Withdrawn EP1370252A4 (fr) 2001-03-01 2002-03-01 Mimetiques de la thrombopoietine

Country Status (2)

Country Link
EP (1) EP1370252A4 (fr)
WO (1) WO2002085343A1 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
TWI280128B (en) 2002-05-22 2007-05-01 Smithkline Beecham Corp 3'-[(2Z)-[1-(3,4- dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazino]-2'-hydroxy-[1,1'-biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1552828A4 (fr) 2002-08-14 2007-01-24 Nissan Chemical Ind Ltd Activateur du recepteur de la thrombopoietine et procede de production
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
US20070105824A1 (en) * 2003-04-29 2007-05-10 Erickson-Miller Connie L Methods for treating degenerative diseases/injuries
UA82695C2 (uk) * 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
CN100443472C (zh) * 2003-06-06 2008-12-17 日产化学工业株式会社 3-亚烷基肼基取代的杂芳基化合物以及含有其的药物
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2006062240A1 (fr) 2004-12-08 2006-06-15 Nissan Chemical Industries, Ltd. Composes heterocycliques a substitution 3-ethylidenehydrazino utilises en tant qu’activateurs du recepteur de la thrombopoietine
CA2590204C (fr) 2004-12-14 2012-12-04 Nissan Chemical Industries, Ltd. Compose d'amide et activateur du recepteur de la thrombopoietine
AU2006270801B2 (en) 2005-07-15 2011-12-22 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
EP1947101A4 (fr) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd Composé de type hydrazide et activateur du récepteur de la thrombopoïétine
CA2630234A1 (fr) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Composes modulant l'activite thrombopoietine et procedes correspondants
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
WO2010138656A1 (fr) 2009-05-29 2010-12-02 Glaxosmithkline Llc Procédés d'administration de composés agonistes de la thrombopoïétine
WO2011098095A1 (fr) 2010-02-09 2011-08-18 Aplagen Gmbh Peptides se liant au récepteur de tpo
UA109287C2 (uk) * 2010-11-02 2015-08-10 Солі органічного аміну похідних амінобензойної кислоти і спосіб їх одержання
WO2012102937A2 (fr) 2011-01-25 2012-08-02 Irm Llc Composés qui développent des cellules souches hématopoïétiques
CA2858069C (fr) 2011-12-08 2020-02-11 Fred Hutchinson Cancer Research Center Compositions et procedes pour la generation amelioree de cellules souches/progenitrices hematopoietiques
AU2013212457B2 (en) 2012-01-27 2017-02-16 Universite De Montreal Pyrimido[4,5-b]indole derivatives and use thereof in the expansion of hematopoietic stem cells
CN104628647A (zh) * 2013-11-12 2015-05-20 上海医药工业研究院 3-甲基-1-(3,4-二甲基苯基)-2-吡唑啉-5-酮的制备方法
CA2946446C (fr) 2014-04-22 2020-11-03 Universite De Montreal Composes de pyrido-pyrrolo-pyrimidine et de pyrido-indole, compositions pharmaceutiques contenant ces composes et leur utilisation dans l'expansion de cellules souches hematopoietiques et/ou de cellules progenitrices hematopoietiques
SG11201703407UA (en) 2014-10-31 2017-05-30 Nissan Chemical Ind Ltd Ligand-binding fiber and cell culture substrate using said fiber
CN110467531B (zh) * 2018-05-09 2022-04-19 新发药业有限公司 一种3’-硝基-2’-羟基联苯-3-甲酸的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035446A1 (fr) * 1998-12-17 2000-06-22 Smithkline Beecham Corporation Mimetiques de thrombopoietine
WO2001017349A1 (fr) * 1999-09-10 2001-03-15 Smithkline Beckman Corporation Mimétiques de thrombopoïétine
WO2001089457A2 (fr) * 2000-05-25 2001-11-29 Smithkline Beecham Corporation Mimiques de thrombopoietine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035446A1 (fr) * 1998-12-17 2000-06-22 Smithkline Beecham Corporation Mimetiques de thrombopoietine
WO2001017349A1 (fr) * 1999-09-10 2001-03-15 Smithkline Beckman Corporation Mimétiques de thrombopoïétine
WO2001089457A2 (fr) * 2000-05-25 2001-11-29 Smithkline Beecham Corporation Mimiques de thrombopoietine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EL LATIF, F. M. A.: "An improved synthesis of pyrazolo(3,4-b)(1,5) , benzoxazepine, -benzothiazepine and -benzodiazepine derivatives via a convenient one-pot synthesis.", JOURNAL OF HETEROCYCLIC CHEMISTRY., vol. 37, no. 6, 2000, US HETEROCORPORATION. PROVO., pages 1659 - 1662, XP002366337 *
See also references of WO02085343A1 *

Also Published As

Publication number Publication date
WO2002085343A1 (fr) 2002-10-31
EP1370252A1 (fr) 2003-12-17

Similar Documents

Publication Publication Date Title
IL193617A0 (en) Thrombopoietin mimetics
EP1370252A4 (fr) Mimetiques de la thrombopoietine
EP1349613A4 (fr) Mimetiques de thrombopoietine
AU2003297925A8 (en) Thrombopoietin mimetics
EP1556059A4 (fr) Mimetiques de la thrombopoietine
GB2380760B (en) Retaining member
GB2385939B (en) Combination square
GB2384041B (en) Combination fitting
PL367864A1 (en) Novel combination
AU2002258438A1 (en) Thrombopoietin mimetics
GB0130724D0 (en) Bacteriophage
HU0100486D0 (en) Bolyhos spirit
GB0128234D0 (en) Antimicrobial agents
GB0116864D0 (en) Antimicrobial agents
AU146628S (en) Section
PL112794U1 (en) Section
PL112804U1 (en) Section
PL112801U1 (en) Section
PL112802U1 (en) Section
PL112803U1 (en) Section
AU149609S (en) Section
AU146768S (en) Section
PL112800U1 (en) Section
GB0126334D0 (en) Numbers
GB0109229D0 (en) Boss

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030925

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060222

17Q First examination report despatched

Effective date: 20061214

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GLAXOSMITHKLINE LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100615